Quantification of F2-Isoprostanes in Biological Fluids and Tissues as a Measure of Oxidant Stress

Methods in Enzymology

Volumn 433, Issue , 2007, Pages 113-126

  Milne, Ginger L ^a   Yin, Huiyong ^a   Brooks, Joshua D ^a   Sanchez, Stephanie ^a   Jackson Roberts II, L ^a   Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BIOCHEMICAL MARKER; ISOPROSTANE DERIVATIVE;

ACCURACY; ANALYTIC METHOD; ANIMAL TISSUE; BODY FLUID; DERIVATIZATION; EXTRACTION; GAS CHROMATOGRAPHY; HUMAN; HYDROLYSIS; IN VITRO STUDY; ION MONITORING; LIPID PEROXIDATION; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; RAT; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; ANIMAL; ARTICLE; CHEMISTRY; ISOLATION AND PURIFICATION; MASS FRAGMENTOGRAPHY; METHODOLOGY;

ANIMALS; BODY FLUIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOPROSTANES; LIPID PEROXIDATION; OXIDATIVE STRESS;

EID: 38449117165     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)33006-1     Document Type: Review

References (36)

1. Basu S., Whiteman M., Mattey D.L., and Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann. Rheum. Dis. 60 (2001) 627-631
2. Chisholm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic. Biol. Med. 18 (2000) 1815-1826
3. Davi G., Alessandrini P., Mezzetti A., Minotti G., Bucciarelli T., Costantini F., Cipollone F., Bon G.B., Ciabattoni G., and Patrono C. In vivo formation of 8-epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3230-3235
4. Davi G., Guagnano M.T., Ciabattoni G., Basili S., Falco A., Marinopiccoli M., Nutini M., Sensi S., and Patrono C. Platelet activation in obese women: Role of inflammation and oxidant stress. JAMA 288 (2002) 2008-2014
5. Davies S.S., Zackert W., Luo Y., Cunningham C.C., Frisard M., and Roberts II L.J. Quantification of dinor, dihydro metabolites of F2-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal. Biochem. 348 (2006) 185-191
6. Dietrich M., Block G., Hudes M., Morrow J.D., Norkus E.P., Traber M.G., Cross C.E., and Packer L. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 7-13
7. Famm S.S., and Morrow J.D. The isoprostanes: Unique products of arachidonic acid oxidation-a review. Curr. Med. Chem. 10 (2003) 1723-1740
8. Gniwotta C., Morrow J.D., Roberts II L.J., and Kuhn H. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3236-3241
9. Gopaul N.K., Anggard E.E., Mallet A.I., Betteridge D.J., Wolff S.P., and Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368 (1995) 225-229
10. Gross M., Steffes M., Jacobs Jr. D.R., Yu X., Lewis L., Lewis C.E., and Loria C.M. Plasma F2-isoprostanes and coronary artery calcification: The CARDIA Study. Clin. Chem. 51 (2005) 125-131
11. Halliwell B., and Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol. 186 (1990) 1-85
12. Haschke M., Zhang Y.L., Kahle C., Klawitter J., Korecka M., Shaw L.M., and Christians U. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin. Chem. 53 (2007) 489-497
13. Kadiiska M.B., Gladen B.C., Baird D.D., Germolec D., Graham L.B., Parker C.E., Nyska A., Wachsman J.T., Ames B.N., Basu S., Brot N., Fitzgerald G.A., et al. Biomarkers of oxidative stress study II: Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic. Biol. Med. 38 (2005) 698-710
14. Keaney Jr. J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., Massaro J.M., Sutherland P., Vita J.A., and Benjamin E.J. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Throm. Vasc. Biol. 23 (2003) 434-439
15. Liang Y., Wei P., Duke R.W., Reaven P.D., Harman S.M., Cutler R.G., and Heward C.B. Quantification of 8-iso-prostaglandin-F(2alpha) and 2,3-dino-8-iso-prostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Free Radic Biol. Med. 34 (2003) 409-418
16. Masoodi M., and Nicolaou A. Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20 (2006) 3023-3029
17. Milne G.L., Musiek E.S., and Morrow J.D. F2-isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers 10 Suppl. 1 (2005) S10-S23
18. 2-isoprostanes as a biomarker of oxidative stress. Nat. Protocols 2 (2007) 221-226
19. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts II L.J., Morrow J.D., and Montine T.J. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids 128 (2004) 117-124
20. Montine T.J., Beal M.F., Robertson D., Cudkowicz M.E., Biaggioni I., O'Donnell H., Zackert W.E., Roberts L.J., and Morrow J.D. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52 (1999) 1104-1105
21. Montine T.J., Markesbery W.R., Morrow J.D., and Roberts II L.J. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44 (1998) 410-413
22. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Throm. Vasc. Biol. 25 (2005) 279-286
23. Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., and Roberts II L.J. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332 (1995) 1198-1203
24. Morrow J.D., Harris T.M., and Roberts II L.J. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184 (1990) 1-10
25. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts II L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87 (1990) 9383-9387
26. Morrow J.D., Chen Y., Brame C.J., Yang J., Sanchez S.C., Xu J., Zackert W.E., Awad J.A., and Roberts L.J. The isoprostanes: Unique prostaglandin like products of free radical-catalyzed lipid peroxidation. Drug Metab. Rev. 31 (1999) 117-139
27. Morrow J.D., Zackert W.E., Yang J.P., Kurhts E.H., Callewaert D., Dworski R., Kanai K., Taber D., Moore K., Oates J.A., and Roberts L.J. Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 269 (1999) 326-331
28. 2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 300 (1999) 3-12
29. Pratico D., Barry O.P., Lawson J.A., Adiyaman M., Hwang S.W., Khanapure S.P., Iuliano L., Rokach J., and FitzGerald G.A. IPF2alpha-I: An index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA 95 (1998) 3449-3454
30. Roberts II L.J., Moore K.P., Zackert W.E., Oates J.A., and Morrow J.D. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. J. Biol. Chem. 271 (1996) 20617-20620
31. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., and FitzGerald G.A. The isoprostanes: A perspective. Prostaglandins 54 (1997) 823-851
32. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., and FitzGerald G.A. Nomenclature of isoprostanes: A proposal. Prostaglandins 54 (1997) 853-873
33. Sircar D., and Subbaiah P.V. Isoprostane measurement in plasma and urine by liquid chromatography-mass spectrometry with one-step sample preparation. Clin. Chem. 53 (2007) 251-258
34. Taylor A.W., Bruno R.S., Frei B., and Traber M.G. Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F-isoprostanes. Anal. Biochem. 350 (2006) 41-51
35. Wang Z., Ciabattoni G., Creminon C., Lawson J., Fitzgerald G.A., Patrono C., and Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J. Pharmacol. Exp. Ther. 275 (1995) 94-100
36. 2-isoprostanes using novel multidimensional solid-phase extraction and LC-MS/MS. J. Lipid Res. 18 (2007) 733-744